Manufacturing Packaging Farmaca (MPF)
Manufacturing Packaging Farmaca (MPF) is recorded as a service provider in 21 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 21 trials · Latest update first
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
Sponsor Corvus Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)
Sponsor University Health Network
- Start (EU)
- Latest update
- Estimated end
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study)
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study)
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder
Sponsor Otsuka Pharmaceutical Development & Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
A long-term, double-blind, randomised, placebo-controlled clinical trial to investigate the efficacy and safety of PQ Grass 27600 SU in children and adolescents with seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen exposure
Sponsor Allergy Therapeutics (UK) Limited
- Start (EU)
- Latest update
- Estimated end
A Phase III, randomised, double-blind, placebo-controlled, parallel-group, pivotal trial to assess the efficacy and safety of sonlicromanol in adult subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G variant.
Sponsor Khondrion B.V.
- Start (EU)
- Latest update
- Estimated end
A PHASE 3 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PLOZASIRAN IN ADULTS WITH HYPERTRIGLYCERIDEMIA (SHASTA-10 STUDY)
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study)
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Sponsor Cardurion Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Of 501 screened subjects, 224 were screen failures, including 198 who did not meet eligibility criteria.
- Thirty screened subjects at a single site were disqualified because of a Good Clinical Practice breach.
- Twenty-six subjects randomized at Site 1903 were excluded from the ITT population.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
Sponsor Intercept Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
Sponsor Corcept Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Evaluation of Safety, Tolerability and Efficacy of Crofelemer following Multiple Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Participants with Microvillus Inclusion Disease (MVID)
Sponsor Napo Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of adult patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon in continuity (CIC)
Sponsor Napo Therapeutics S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Subjects with Moderate-to-Severe Plaque Psoriasis
Sponsor Can-Fite Biopharma Ltd.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Sponsor Shanghai Henlius Biotech Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1/2a Trial to Evaluate the Safety, Tolerability and Efficacy of Nebulised RESP30X Nitric Oxide Formulations in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients with Pseudomonas Aeruginosa (Pa) or other Potentially Pathogenic Micro-organisms (PPMs).
Sponsor Thirty Respiratory Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
Sponsor University College London
- Start (EU)
- Latest update
- Estimated end
A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy
Sponsor Rapt Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Manufacturing Packaging Farmaca (MPF)?
The 2026-10-09 snapshot links Manufacturing Packaging Farmaca (MPF) to 21 distinct CTIS trials. Recorded services include Medicinal product management, Labelling and packaging, EU Qualified Person (QP) release, Interactive response technology (IRT), among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Manufacturing Packaging Farmaca (MPF)?
The most frequently recorded therapeutic areas are Metabolic Disorders, Cardiology, Allergy, Dermatology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Manufacturing Packaging Farmaca (MPF) conducted?
The linked trials record locations in 24 countries, including Spain, Poland, Bulgaria, Czechia, Germany. These are trial locations, not confirmed office locations or countries where Manufacturing Packaging Farmaca (MPF) delivered services.
What can this page tell me about Manufacturing Packaging Farmaca (MPF)'s trial experience?
Browse 21 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Manufacturing Packaging Farmaca (MPF). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Manufacturing Packaging Farmaca (MPF) B.V.